ACS Medicinal Chemistry Letters · 2018 · 54 citations · 20 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceDrug DiscoveryMedical MicrobiologyAntibacterial AgentsAntibacterial PharmacologyAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceResistance In Gram-negative BacteriaAnti-biofilm StrategiesAntibacterial Drug DevelopmentAntibiotic DiscoveryBacterial Biofilm ControlBiofilm InhibitorsBiofilm-disrupting AgentsMultidrug-resistant PathogensNovel Antibacterial Agents
In the last 30 years, development of new classes of antibiotics has slowed, increasing the necessity for new options to treat multidrug resistant bacterial infections. Development of antibiotic adjuvants that increase the effectiveness of currently available antibiotics is a promising alternative approach to classical antibiotic development. Reports of the ability of the natural product meridianin D to modulate bacterial behavior have been rare. Herein, we describe the ability of meridianin D to inhibit biofilm formation of methicillin-resistant Staphylococcus aureus (MRSA) and to increase the potency of colistin against colistin-resistant and sensitive Gram-negative bacteria. Analogues were identified that are capable of inhibiting and dispersing MRSA biofilms and lowering the colistin MIC to below the CLSI breakpoint against Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli.
20
Yiyun Liu, Yang Wang, Timothy R. Walsh et al. · The Lancet Infectious Diseases · 2015 · 5.4K citations
Lei Chen, Randall L. Todd, Julia A. Kiehlbauch et al. · MMWR Morbidity and Mortality Weekly Report · 2017 · 168 citations · Full text